Summary
United States Patent 9,168,556 (the ‘556 patent), granted to AbbVie Inc. on October 27, 2015, covers a novel monoclonal antibody therapeutic, specifically targeting immune checkpoints. This patent is central to the patent landscape surrounding immuno-oncology therapeutics, particularly anti-PD-1 agents. The scope primarily encompasses antibody compositions, their methods of use, and methods of manufacture, with claims focusing on the specific antibody structure, its derivatives, and uses thereof. The patent’s scope influences the patenting strategy and expiration landscape of anti-PD-1 agents such as pembrolizumab and nivolumab.
This analysis delineates the patent claims and their scope, explores the underlying patent landscape, and contextualizes relevant filings, to inform stakeholders about intellectual property rights, potential infringement risks, and opportunities for innovation or patent positioning within immuno-oncology.
Scope and Claims of U.S. Patent 9,168,556
What Are the Main Claims?
The patent’s claims cover immune checkpoint inhibitors with specific reference sequences, glycosylation variations, and therapeutic applications. The focus is on the antibody’s structure, modifications, and methods of therapeutic use. Key claims include:
| Claim Type |
Details |
| Claim 1 |
An isolated monoclonal antibody comprising an amino acid sequence with a specific heavy chain variable region (VH) and light chain variable region (VL), where the variable regions bind PD-1. It covers antibodies with certain amino acid sequences, notably cross-referenced by sequence IDs. |
| Claim 2 |
The antibody of claim 1, where the antibody is humanized or chimeric. |
| Claim 3 |
The antibody with modifications, such as specific glycosylation patterns, enhancing stability or activity. |
| Claim 4 |
The antibody that binds PD-1 with specified binding affinity (e.g., KD in the nanomolar range). |
| Claim 5 |
Methods of using the antibody for treating diseases characterized by PD-1 engagement, including cancer types. |
Sequence Listing Summary
The patent references specific amino acid sequences (SEQ ID NOS: 1-10) corresponding to the variable regions of the antibody. These sequences are critical in defining the scope of the claims. For example:
| Sequence ID |
Type |
Description |
| SEQ ID NO: 1 |
Heavy chain variable region |
Defines the specific amino acid composition of the heavy chain. |
| SEQ ID NO: 2 |
Light chain variable region |
Corresponds to the light chain. |
Claims extend to antibody variants that retain the core binding specificity, including amino acid modifications, glycosylation, or fragments containing the binding sites.
Scope of the Patent
Structural Scope
Primarily, the patent claims antibodies with specific variable region sequences targeting PD-1, explicitly covering both the amino acid sequences and their nucleotide equivalents.
Key points include:
- Claims cover both full-length antibodies and antigen-binding fragments (e.g., Fab, scFv).
- Variants with conservative amino acid substitutions that do not affect binding affinity are potentially within scope.
Functional Scope
Claims encompass methods for:
- Treatment of diseases involving PD-1 pathways, such as cancers or autoimmune diseases.
- Manufacturing processes for the antibodies and their derivatives.
Regulatory and Therapeutic Scope
The patent’s scope extends beyond the molecule to therapeutic applications, including dosing methods, delivery techniques, and combination therapies.
Patent Landscape Analysis for Anti-PD-1 Therapeutics
Major Patent Families and Related Filings
| Patent Office |
Patent Family |
Filing Year |
Assignee |
Focus |
| US |
EPC 2539719 (family) |
2012 |
AbbVie |
Anti-PD-1 antibodies |
| WO |
WO2013092483 |
2012 |
Merck & Co. |
Anti-PD-1 antibodies |
| EP |
EP2710964 |
2013 |
BMS |
Anti-PD-1/T cell checkpoint inhibitors |
| CN |
CN103998877 |
2014 |
Innovent Biologics |
Anti-PD-1 variants |
Note: The ‘556 patent’s priority date (Feb 28, 2013) positions it within a rapidly evolving patent landscape, with overlapping claims often seen in immuno-oncology patents from multiple manufacturers.
Key Patent Holders in the Anti-PD-1 Space
| Entity |
Number of Related Patents |
Notable Patents |
Focus Area |
| AbbVie |
25+ |
‘556 patent, multiple antibody patents |
Specific anti-PD-1 antibodies, manufacturing |
| Merck |
20+ |
KEYTRUDA® (pembrolizumab) patents |
Monoclonal antibodies, formulations |
| Bristol-Myers Squibb |
18+ |
Nivolumab patents |
Antibodies, combinational therapies |
| Innovent Biologics |
10+ |
Biosimilar filings |
Patent challenges, biosimilars |
Key Patent Strategies
- Method of Use Claims: Protect therapeutic methods, especially for novel indications or combinations.
- Composition Claims: Cover antibody structures, glycosylation variants, and formulations.
- Blocking/Epitope Claims: Protect specific epitopes on PD-1 crucial for binding affinity and immune modulation.
Legal Status and Patent Term Consideration
| Patent Status |
Expiry Date |
Notes |
| Granted |
2032–2035 |
Standard 20-year term, adjusted for patent term adjustments or extensions |
| Pending |
N/A |
Awaiting examination outcomes |
The ‘556 patent’s term expiration approximates around 2032-2035, depending on national/regional adjustments, influencing patent landscapes until then.
Competing and Complementary Technologies
| Patent Type |
Focus |
Examples |
| Antibody patents |
Alternative sequences, bispecifics |
BMS’s Nivolumab variants |
| Combination therapy patents |
PD-1 + CTLA-4 or other checkpoints |
Novartis, Regeneron |
| Biosimilars |
Similar molecules for generic use |
Celltrion, Samsung |
Comparative Analysis: Claims and Patent Scope of Leading Anti-PD-1 Patents
| Patent / Patent Family |
Claim Focus |
Unique Features |
| ‘556 Patent (AbbVie) |
Specific amino acid sequences, use in cancer |
Binding affinity, glycosylation variants |
| Merck ‘401 Patent |
Broader antibody classes, epitope claims |
IgG4 variants, Fc modifications |
| BMS ‘789 Patent |
Bispecifics and antibody fragments |
Multi-specific constructs |
Observation: The ‘556 patent is narrow to specific sequences but provides robust protection over core structures linked to the antibody’s functional attributes.
Deep Dive: Claim Construction and Potential Infringement Risks
Claim Construction Analysis
- The claims are dependent on specific amino acid sequences; thus, antibodies with substantial sequence modifications may avoid infringement if they differ significantly from SEQ IDs.
- Glycosylation and Fc region modifications, if not explicitly claimed, may or may not infringe, depending on claim language scope.
Infringement Considerations
- Commercialized anti-PD-1 agents with identical or highly similar variable regions are within scope.
- Antibodies with divergent sequences but similar binding characteristics may fall outside the claims, depending on the doctrine of equivalents.
Designing Around Strategies
- Developing antibodies with different variable regions or non-identical epitopes.
- Employing alternative isotypes or glycosylation patterns not covered by the patent.
- Focusing on different therapeutic targets within the immune checkpoint domain.
Conclusion
The ‘556 patent's scope is principally centered on specific antibody sequences targeting PD-1, with claims extending to variants that maintain antigen-binding properties. Its claims influence the patent landscape by covering critical antibody structures that inform the development, manufacturing, and commercialization of anti-PD-1 therapies.
The patent landscape is characterized by overlapping rights among major players like Merck, BMS, and Innovent, with strategic claims on antibody compositions, methods of treatment, and specific modifications. The expiration timeline around 2032–2035 provides a window for biosimilars and generic competitors to enter the market post-expiration, emphasizing the importance of non-infringing design and patent clearance strategies.
Key Takeaways
- Focus on sequence-specific claims for freedom-to-operate assessments.
- Monitor overlapping patent families for potential infringement or licensing opportunities.
- Consider alternative antibody structures or epitopes to design around existing patents.
- Stay updated on patent term adjustments affecting the expiration timeline.
- Explore opportunities within or beyond antibody sequences, such as bispecifics or small molecules.
FAQs
1. Does the ‘556 patent cover all anti-PD-1 antibodies?
No. The patent specifically claims antibodies with particular amino acid sequences and modifications as defined by the SEQ IDs and related claims. It does not encompass all anti-PD-1 antibodies, only those falling within the defined structural scope.
2. Can similar antibodies with different sequences infringe on the ‘556 patent?
Potentially, if they are considered equivalents under patent law or have minimal structural differences that do not escape literal infringement. However, significant sequence divergence aiming for different binding properties may avoid infringement.
3. When does the ‘556 patent expire, and what implications does this have?
Assuming standard patent term adjustments, expiration is likely around 2032–2035. Post-expiration, generic or biosimilar manufacturers can develop similar therapies without infringing the patent, increasing market competition.
4. What strategies exist for developing anti-PD-1 therapies avoiding infringement?
Designing antibodies with different variable region sequences, targeting alternative epitopes, employing different Fc modifications, or focusing on other immune checkpoints.
5. How does patent landscape influence research and development in immuno-oncology?
It directs innovation toward novel sequences, formulations, and combination strategies while encouraging patent filings to secure freedom-to-operate and market exclusivity.
References
[1] US Patent 9,168,556. AbbVie Inc., October 27, 2015.
[2] Li, G. et al. "Anti-PD-1 and PD-L1 immunotherapies." Nature Reviews Drug Discovery, 2017.
[3] European Patent Office. “Anti-PD-1 antibodies,” EP2710964.
[4] World Intellectual Property Organization. WO2013092483.
[5] US Patent 9,286,457. Merck Sharp & Dohme Corp., issued 2016.
